Our results demonstrate a dramatic reduction in tumor weight, transendothelial migration, and distal metastasis upon inducing CRISPR-modification of OX-40 expression in CTCL cells through the ERK1/2 pathway. The gene discussed is MAPK3; the disease is neoplasm.